Trial Profile
A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 12 Nov 2020 According to Sunovion Pharmaceuticals media release, the European Medicines Agency (EMA) has approved Latuda (lurasidone) for the treatment of Adolescent Schizophrenia in patients starting from 13 years of age.
- 15 Sep 2020 Results (n=537) of post-hoc pooled analysis assessing safety and efficacy of Lurasidone from six double blind, placebo-controlled, 6 weeks clinical studies in adolescents and young adults with schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 02 May 2018 According to a Sunovion Pharmaceuticals media release, data from the interim analysis of the 24-Month, open-label extension study will be presented at the American Psychiatric Association (APA) Annual Meeting (2018).